

Market Round-up

Proudly sponsored by:

FRESH
PERSPECTIVES

V19 – 28th September, 2018

General Market News:

- **HSE** reports rise in uptake of **HPV vaccine**
[LINK](#)
- Major **Takeda** shareholder “sceptical” about **Shire** takeover
[LINK](#)
- **Ferring Pharmaceuticals** has launched testosterone replacement therapy **Testavan** in the UK.
[LINK](#)
- **NICE** has published draft guidelines rejecting NHS use of **CSL Behring’s Respreeza**
[LINK](#)
- **Lilly’s** snaps up **Chugai’s** experimental diabetes drug
[LINK](#)
- **GSK’s** popular new shingles vaccine, **Shingrix**, faces shortages due to high demands.
[LINK](#)
- **Novartis** slashes thousands of jobs in Switzerland & UK
[LINK](#)
- First cancer drug from **Amgen/Astellas** JV approved in Japan
[LINK](#)
- **GSK** vaccine prevents **tuberculosis** in HIV negative adults
[LINK](#)

Biosimilars:

- **Sandoz’s** proposed biosimilar **pegfilgrastim**, a drug used in the support of chemotherapy patients, has received a positive recommendation from the EMA
[LINK](#)
- **Pfizer** facing difficult path to ramp up biosimilar business
[LINK](#)

NCPE Drug Updates

The NCPE have recommended a full pharmacoeconomic assessment for **Roche’s Atezolizumab**
[LINK](#)

Drug Approvals:

- **Amgen's Neulasta** has a new competitor in Europe as the EC approved **Coherus BioSciences'** marketing application for **UDENYC**
- **AstraZeneca's Imfinzi** has been approved in Europe for the treatment of locally-advanced, unresectable non-small cell lung cancer (NSCLC).
[LINK](#)
- Two drugs from **Novartis - Gilenya**, a multiple-sclerosis drug, and **Luxturna**, used to treat children and adults with a rare inherited retinal disease have received a positive recommendation from the EMA
[LINK](#)
- **Shire** gets Japanese approval for rare genetic disease drug **Firazyr**
[LINK](#)
- The FDA have approved the use of **Eli Lilly's** non-opioid pain drug **Emgality** for the prevention of migraine.
[LINK](#)
- **Pfizer's Vizimpro** has been approved in the US as a treatment for some forms of lung cancer.
[LINK](#)

Drug Approval Submissions:

- **Novartis** to file for new **Lucentis (ranibizumab)** indication in retinopathy of prematurity (ROP), a rare disease in premature infants that often leads to blindness
[LINK](#)

Further Reading:

Novartis is slated to lead all pharma players in 2024 sales, where does everyone else fall?

[LINK](#)

'It's life or death for these kids' - parents anxiously wait for HSE decision on 'miracle' drug **Spinraza** from **Biogen**

[LINK](#)

FRESH
PERSPECTIVES

Fresh Perspectives specialise in Pharmaceutical market research in Ireland, with all types of Healthcare Professionals and patients in all therapy areas. They cover a wide range of qualitative and quantitative methodologies from Online surveys through to Focus Groups.